UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

The Lancet (British edition), 2011-07, Vol.378 (9787), p.238-246

2011

Volltextzugriff (PDF)

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

The Lancet (British edition), 2011-07, Vol.378 (9787), p.229-237

2011

Volltextzugriff (PDF)

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

Antimicrobial Agents and Chemotherapy, 2010-02, Vol.54 (2), p.718-727

2010

Volltextzugriff (PDF)

Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO)

Antiviral therapy, 2014-01, Vol.19 (2), p.191-200

2014

Volltextzugriff (PDF)

A human homologue of the Drosophila eyes absent gene underlies Branchio-Oto-Renal (BOR) syndrome and identifies a novel gene family

Nature genetics, 1997-02, Vol.15 (2), p.157-164

1997

Volltextzugriff (PDF)

Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis

Journal of acquired immune deficiency syndromes (1999), 2012-01, Vol.59 (1), p.39-46

2012

Volltextzugriff (PDF)

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial

AIDS research and human retroviruses, 2012-05, Vol.28 (5), p.437-446

2012

Volltextzugriff (PDF)

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

AIDS (London), 2013-03, Vol.27 (6), p.939-950

2013

Volltextzugriff (PDF)

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

Journal of acquired immune deficiency syndromes (1999), 2012-05, Vol.60 (1), p.33-42

2012

Volltextzugriff (PDF)

96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials

Antiviral therapy, 2013-01, Vol.18 (8), p.967-977

2013

Volltextzugriff (PDF)

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

AIDS (London), 2010-01, Vol.24 (1), p.55-65

2010

Volltextzugriff (PDF)

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response

Antiviral therapy, 2013-01, Vol.18 (2), p.253-256

2013

Volltextzugriff (PDF)

Anemia, Blood Loss, and Blood Transfusions in North American Children in the Intensive Care Unit

American journal of respiratory and critical care medicine, 2008-07, Vol.178 (1), p.26-33

2008

Volltextzugriff (PDF)

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes

Kidney international, 2005-06, Vol.67 (6), p.2346-2353

2005

Volltextzugriff (PDF)

Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine

AIDS reviews, 2013-04, Vol.15 (2), p.87-101

2013

Volltextzugriff (PDF)

Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine

Journal of clinical pharmacology, 2013-08, Vol.53 (8), p.834-840

2013

Volltextzugriff (PDF)

Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir

Drugs in R&D, 2018-09, Vol.18 (3), p.199-210

2018

Volltextzugriff (PDF)

Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery

Nephrology, dialysis, transplantation, 2005-05, Vol.20 (suppl-3), p.iii33-iii40

2005

Volltextzugriff (PDF)

Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine: The Journal of Clinical Pharmacology

Journal of clinical pharmacology, 2013-08, Vol.53 (8), p.834-840

2013

Volltextzugriff (PDF)

Correction to: Evaluation of Cardiovascular Disease Risk in HIV‑1–Infected Patients Treated with Darunavir

Drugs in R&D, 2018-09, Vol.18 (3), p.249-250

2018

Volltextzugriff (PDF)

Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents

AIDS (London), 2012-02, Vol.26 (4), p.447-455

2012

Volltextzugriff (PDF)

Reactions to Eprex's adverse reactions

Nature biotechnology, 2006-10, Vol.24 (10), p.1199-1200

2006

Volltextzugriff (PDF)

Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery

Nephrology, dialysis, transplantation, 2006-09, Vol.21 (9), p.2678-2678

2006

Volltextzugriff (PDF)

Epoetin-associated pure red cell aplasia in patients with chronic kidney disease : solving the mystery: Treatment of renal anaemia in maintenance dialysis patients: an update

Nephrology, dialysis, transplantation, 2005, Vol.20, p.iii33-iii40

2005

Volltextzugriff (PDF)

Issues Related to Organ Development: Renal

Pediatric Drug Development,2, 2013, p.409-418

2013

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(25)

Publikationsform

Sprache

Englisch
(31)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(26)
Science & Technology
(26)
Humans
(23)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Male
(14)
Infectious Diseases
(13)
Rilpivirine
(13)
Adult
(11)
Female
(11)
Anti-Hiv Agents - Therapeutic Use
(10)
Hiv Infections - Drug Therapy
(10)
Human Viral Diseases
(10)
Immunology
(10)
Pharmacology. Drug Treatments
(10)
Viral Diseases
(10)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(10)
Virology
(10)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(9)
Antiviral Agents
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO)

A human homologue of the Drosophila eyes absent gene underlies Branchio-Oto-Renal (BOR) syndrome and identifies a novel gene family

Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response

Anemia, Blood Loss, and Blood Transfusions in North American Children in the Intensive Care Unit

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes

Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine

Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine

Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir

Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery

Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine: The Journal of Clinical Pharmacology

Correction to: Evaluation of Cardiovascular Disease Risk in HIV‑1–Infected Patients Treated with Darunavir

Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents

Reactions to Eprex's adverse reactions

Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery

Epoetin-associated pure red cell aplasia in patients with chronic kidney disease : solving the mystery: Treatment of renal anaemia in maintenance dialysis patients: an update

Issues Related to Organ Development: Renal

Suchergebnisse filtern